iBio
IBIO | NASDAQ
$0.71
-$0.02 (-2.97%)
At close: Nov 16, 2026, 4:00 PM ET
$0.69
-$0.02 (-2.11%)
After-hours:
Nov 16, 2026, 7:55 PM ET
iBio Company Profile
Company profile explainedCompany Profile
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
Key Executives
| Name | Position |
|---|---|
| Martin Brenner | Chief Executive Officer, Chief Scientific Officer & Director |
| Marc Banjak | Chief Legal Officer |
| Cory Schwartz | Director of Research and Early Development |
| Felipe Duran | CFO & Principal Accounting Officer |
| Molly Carr | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 19, 2026 | 8-K | Current Report |
| Oct 15, 2026 | 4 | Filing |
| Oct 15, 2026 | 4 | Filing |
| Oct 15, 2026 | 4 | Filing |
| Oct 15, 2026 | 4 | Filing |
| Oct 15, 2026 | 4 | Filing |
| Oct 15, 2026 | 4 | Filing |
| Oct 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 13, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 8-K | Current Report |
iBio
| Country | United States |
| IPO Date | Aug 19, 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Martin Brenner |
Contact Details
11750 Sorrento Valley Road San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | IBIO |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001420720 |
| CUSIP Number | 451033708 |
| ISIN Number | US4510337086 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove IBIO